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[1–15]; and Cohort C: 5 [1–20]), of which 24 were eligi-
ble for pharmacokinetic analysis (eight in each cohort). For 
moderate and severe renal impairment versus normal renal 
function, GMR estimates were: clearance normalized to 
body surface area (CL/BSA) 0.95 (90% CI 0.80–1.13) and 
0.89 (0.61–1.32); area under the curve normalized to dose 
(AUC/dose) 1.06 (0.88–1.27) and 1.14 (0.76–1.71); and FU 
0.99 (0.94–1.04) and 0.97 (0.87–1.09), respectively. Esti-
mated slopes of linear regression of log parameters versus 
log CrCL (renal impairment) were: CL/BSA 0.06 (−0.15 
to 0.28); AUC/dose −0.07 (−0.30 to 0.16); and FU 0.02 
(−0.05 to 0.08). Cabazitaxel safety profile was consistent 
with previous reports.
Conclusions Renal impairment had no clinically meaning-
ful effect on cabazitaxel pharmacokinetics.
Keywords Cabazitaxel · Renal impairment · 
Pharmacokinetics · Phase I · Advanced solid tumors
Abstract 
Purpose Limited data are available on cabazitaxel phar-
macokinetics in patients with renal impairment. This open-
label, multicenter study assessed cabazitaxel in patients 
with advanced solid tumors and normal or impaired renal 
function.
Methods  Cohorts A (normal renal function: creatinine 
clearance [CrCL] >80 mL/min/1.73 m2), B (moderate 
renal impairment: CrCL 30 to <50 mL/min/1.73 m2) and C 
(severe impairment: CrCL <30 mL/min/1.73 m2) received 
cabazitaxel 25 mg/m2 (A, B) or 20 mg/m2 (C, could be 
escalated to 25 mg/m2), once every 3 weeks. Pharmacoki-
netic parameters and cabazitaxel unbound fraction (FU) 
were assessed using linear regression and mixed models. 
Geometric mean (GM) and GM ratios (GMRs) were deter-
mined using mean CrCL intervals (moderate and severe 
renal impairment: 40 and 15 mL/min/1.73 m2) versus a 
control (90 mL/min/1.73 m2).
Results Overall, 25 patients received cabazitaxel (median 
cycles: 3 [range 1–20]; Cohort A: 5 [2–13]; Cohort B: 3 
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Introduction
Impaired renal function is often observed in patients with 
solid tumors, with 40–60% reporting abnormal or impaired 
renal function across several studies [1–8]. Renal impair-
ment can be the result of advanced age or chronic comor-
bidities, such as diabetes, hypertension or kidney disease, 
or can be caused by the cancer itself or the cancer treat-
ment received [1, 8–13]. Several cancer therapies are 
nephrotoxic, including some chemotherapies, targeted 
agents, analgesics, radiopharmaceuticals, radiology con-
trast agents and antiresorptive agents [1]. For some anti-
cancer therapies, including cisplatin, renal impairment is 
a contraindication; for example, 40–50% of patients with 
advanced bladder cancer cannot receive cisplatin because 
of its associated nephrotoxicity [8]. Renal impairment in 
patients receiving treatment for cancer is often associated 
with diminished drug metabolism and metabolite excre-
tion, along with changes in absorption, renal and hepatic 
metabolism, and plasma protein binding and distribution, 
which all lead to altered pharmacokinetics (PK) of the drug 
received [11–13].
In the Renal Insufficiency and Anticancer Medications 
(IRMA) study, of 4684 patients with solid tumors (breast, 
colorectal cancer, lung, ovarian and prostate cancer), 57 and 
53% of patients had renal impairment, depending on the 
type of formula used to calculate renal function, and of the 
222 patients with prostate cancer, 63 and 56% of patients 
presented with renal impairment [2, 5]. Cabazitaxel is a 
second-generation taxane that has demonstrated efficacy 
in the second-line treatment of castration-resistant pros-
tate cancer after docetaxel-based treatment [14]. Although 
renal elimination of cabazitaxel is minimal (approximately 
2.3% is excreted renally as unchanged drug) [10, 15, 16], 
previous studies of cabazitaxel in patients with solid tumors 
have generally excluded patients with renal impairment 
[14, 17]. Some data on the PK of cabazitaxel in patients 
with renal impairment are available from a population PK 
analysis of phase I–III trials [16]. Of 170 patients included 
in this analysis, 59 patients had mild renal impairment, 14 
patients had moderate renal impairment, and one patient 
had severe renal impairment. As expected with the minimal 
renal elimination of cabazitaxel, the population PK analysis 
did not identify renal impairment as a significant covariate 
influencing cabazitaxel PK.
The present study was performed to confirm the results 
of the previous population PK analysis [16] and to provide 
guidance regarding cabazitaxel dosing in patients with 
renal impairment. This study assessed the PK and safety 
of cabazitaxel in patients with advanced solid tumors and 
moderate or severe renal impairment compared with nor-
mal renal function. The primary objective of this study 
was to assess the effect of moderate and severe renal 
impairment on the PK of cabazitaxel. The secondary objec-
tive was to assess the safety of cabazitaxel in patients with 
moderate and severe renal impairment.
Materials and methods
Study design
This was an open-label, multicenter, phase I study 
(NCT01527929) in patients with advanced solid tumors 
and varying degrees of stable, chronic renal impairment 
or normal renal function. Patients were enrolled into one 
of three cohorts at seven institutions across five countries. 
Renal function cohorts were defined by creatinine clear-
ance (CrCL), calculated using the Chronic Kidney Disease 
Epidemiology Collaboration equation (CKD-EPI) formula 
[18–20]. Patients were enrolled into Cohort A: normal renal 
function (CrCL >80 mL/min/1.73 m2), Cohort B: moder-
ate renal impairment (CrCL ≥30 to <50 mL/min/1.73 m2) 
or Cohort C: severe renal impairment (CrCL <30 mL/
min/1.73 m2).
Cabazitaxel was provided as a sterile non-pyrogenic 
solution in 60-mg vials, diluted into a premix solution 
prior to use and administered within 8 h of preparation. All 
patients received 1-h intravenous (IV) infusions of cabazi-
taxel on Day 1 of 3-weekly cycles until unacceptable tox-
icity, disease progression, withdrawal of consent, investi-
gator decision or study cutoff. Cabazitaxel starting doses 
were based on the renal function stratification. Based on 
available PK data for patients with normal renal function 
and moderate renal impairment, no significant changes of 
cabazitaxel PK were expected in these patients. Therefore, 
the approved cabazitaxel dose of 25 mg/m2 was adminis-
tered to patients with normal renal function (Cohort A) or 
moderate renal impairment (Cohort B). For patients with 
severe renal impairment, cabazitaxel starting dose was 
20 mg/m2, escalated to 25 mg/m2 at later cycles if no dose-
limiting toxicities (DLTs) were observed during Cycle 1. 
For Cohort C, PK assessment was carried out at the two 
dose levels for patients who received 25 mg/m2 at later 
cycles. The 20 mg/m2 starting dose was based on a pos-
sible increase in the free fraction of cabazitaxel in patients 
with severe renal impairment due to its high plasma pro-
tein binding (91.6%, mostly to albumin and lipoproteins) 
and the frequency of hypoalbuminemia in such patients. 
DLTs were defined as the following cabazitaxel-related 
adverse events (AEs, as assessed by the investigator): 
grade 2 vomiting and/or diarrhea; grade 3–4 non-hemato-
logic AE (excluding grade 3 fatigue and transaminase or 
bilirubin elevation that returned to baseline prior to next 
treatment cycle); hematologic toxicity, defined as neu-
tropenic infection, febrile neutropenia (fever of unknown 
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origin without documented infection, with grade 3–4 neu-
tropenia), grade 4 neutropenia lasting >7 days, or grade 
3–4 thrombocytopenia. Toxicity and AEs were graded 
and recorded according to National Cancer Institute Com-
mon Terminology Criteria for AEs (NCI CTCAE) v4.03 
[21]. Granulocyte-colony stimulating factor (G-CSF) was 
allowed with therapeutic or prophylactic intent and left to 
the investigator’s judgement.
Patient population
Patients had a diagnosis of a histologically or cytologi-
cally proven non-hematologic malignancy that was refrac-
tory to standard therapy or for which no standard therapy 
was available, and for which cabazitaxel was judged to 
be an adequate treatment option by the investigator. Eligi-
ble patients were ≥18 years of age with a life expectancy 
of >3 months, an Eastern Cooperative Oncology Group 
(ECOG) performance status (PS) of 0, 1 or 2, stable renal 
function (defined as CrCL within a range of ±10% dur-
ing a 3-month period with ≥3 measurements performed), 
and adequate liver and bone marrow function (defined 
as absolute neutrophil count ≥1.5 × 109/L, platelets 
≥100 × 109/L, total bilirubin ≤1.0 × institution upper 
limit of normality [ULN], transaminases ≤2.5 × ULN, 
and alkaline phosphatase ≤2.5 × ULN). Patients must 
have completed prior anticancer therapy ≥4 weeks before 
study entry. Key exclusion criteria included neurotoxic-
ity of grade ≥2, acute renal failure or dialysis that would 
be required during the study, history of hypersensitivity 
to docetaxel or polysorbate 80, known brain metastases, 
and any treatments known to strongly induce CYP3A iso-
enzymes or to strongly inhibit CYP3A4 activity within 
2 weeks before or during the test period for PK sampling. 
The institutional review board at each participating institu-
tion approved the protocol. Written informed consent was 
obtained from all patients. The study was conducted in 
accordance with the ethical principles stated in the Declara-
tion of Helsinki and good clinical practice.
Baseline and on study assessments
Medical histories were recorded at baseline and assessment 
of vital signs, physical examinations, ECOG PS, and elec-
trocardiograms were performed at baseline prior to cabazi-
taxel administration, during study treatment as required 
and ≥30 days after the last administration of study treat-
ment. All signs and symptoms observed from the time of 
informed consent were recorded as AEs. All AEs were 
recorded until 30 days after last administration of study 
treatment. After this follow-up period, only new or ongo-
ing treatment-related AEs were recorded, except for ongo-
ing serious AEs, which were assessed until resolution or 
stabilization, regardless of relationship to study treatment. 
Weekly laboratory evaluations were performed including 
cell blood counts with differentials, and analysis of coag-
ulation, liver function, plasma electrolytes, glucose, albu-
min, total proteins, blood urea nitrogen, creatinine and uri-
nalysis. An eye examination was performed at baseline and 
end of study. CrCL was determined using the CKD-EPI 
formula and if CrCL decreased by 50% from baseline dur-
ing the study, or if dialysis was required, treatment was dis-
continued. The maximum dose delay allowed, due to acute 
toxicity, was 2 weeks. If the treatment gap was longer than 
2 weeks, the patient was discontinued from study treat-
ment. If the dose was reduced due to toxicity, then it was 
not re-escalated. Up to a maximum of two dose reductions 
were allowed per patient. Radiologic studies for disease 
assessment were conducted pretreatment and according to 
the site practice. Tumor response was assessed according to 
the Response Evaluation Criteria in Solid Tumors (RECIST 
1.1).
Pharmacokinetic sampling and bioanalytical 
methodology
Heparinized blood samples were collected from all patients 
for cabazitaxel concentration measurement at Cycle 1 (and 
Cycle 2, or Cycle 3 for one patient, following dose esca-
lation in Cohort C) before start of infusion, 5 min before 
the end of infusion and then 5, 15 and 30 min, and 1, 2, 3, 
5 and 8 h post-infusion, and at approximately 24 (Day 2), 
48 (Day 3), 72 (Day 4), 120 (Day 6), 168 (Day 8) and 216 
(Day 10) h after the end of infusion. The timing of treat-
ment administration and timing of sampling were precisely 
recorded for each patient. Total cabazitaxel concentrations 
in the plasma were determined using a validated liquid 
chromatography with tandem mass spectrometry method 
(LC–MS/MS) with a lower limit of quantification (LLOQ) 
of 1 ng/mL [22, 23]. In addition, blood samples were col-
lected to determine the free, unbound fraction of cabazi-
taxel in all patients at Cycle 1 before start of infusion, 
5 min before the end of infusion, and 3 and 24 h after end 
of infusion. Free cabazitaxel concentrations were deter-
mined after equilibrium dialysis in buffer using a validated 
LC–MS/MS method with a LLOQ of 0.1 ng/mL.
Pharmacokinetic endpoints and analysis
The primary PK endpoints were area under the plasma con-
centration versus time curve (AUC) and cabazitaxel clear-
ance (CL). Secondary PK endpoints included observed 
maximum plasma concentration (Cmax), volume of distribu-
tion at steady state (Vss) and elimination half-life (t1/2ʎ3). Vss 
and CL normalized by body surface area (BSA; Vss/BSA and 
CL/BSA) were also calculated. Total plasma concentrations 
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of cabazitaxel and relative actual time values (as well as 
actual dose) were used to calculate the PK parameters using 
non-compartmental analysis (for Cmax) and individual mod-
eling using a three-compartment open model with first-order 
elimination (for CL, AUC, Vss and t1/2ʎ3). The calculation 
of PK parameters was performed using validated softwares 
(PKDMS version 2 running with WinNonlin Professional, 
version 5.2.1, Pharsight and WinNonlin Professional, version 
6.3, Phoenix, Pharsight), as described previously [24, 25].
Statistical analysis
Sample size for this study was based on empirical consid-
erations and on the experiences in previous population stud-
ies; no formal sample size calculation was performed. A total 
of 24 to 27 patients were expected to be enrolled (at least 8 
patients enrolled and evaluable for final PK evaluation in 
each cohort). One patient with a major deviation (missing 
PK sample at a critical time point) was excluded from the PK 
analysis. Statistical analysis evaluated the effect of population 
group on cabazitaxel PK parameters by modeling the relation-
ship between measures of renal function (CrCL) and the PK 
parameters with a regression model as recommended by the 
United States Food and Drug Administration (FDA) and Euro-
pean Medicines Agency (EMA) [12, 13]. Log-transformed 
PK parameters were analyzed using a linear regression model 
with the independent variable being log-transformed CrCL 
at screening. Log-transformed BSA was a covariate in the 
models except in models using BSA normalized parameters. 
The effect of renal impairment on cabazitaxel PK parameters 
was analyzed using a linear fixed effects model. Geomet-
ric mean estimates were determined using log CrCL values 
corresponding to the mean boundaries of the CrCL interval 
covering the patient cohorts with moderate renal impairment 
(40 mL/min/1.73 m2) and severe renal impairment (15 mL/
min/1.73 m2), along with a value representing the normal pop-
ulation and defined as the control (90 mL/min/1.73 m2). Using 
the regression model parameter estimates, point estimates for 
PK parameters corresponding to CrCL of 90, 40 and 15 mL/
min/1.73 m2 were calculated after converting these values to 
the log scale. Geometric mean estimates were computed, and 
estimates for the geometric mean ratio of each population 
group (40 and 15 mL/min/1.73 m2) versus the control popu-
lation group (90 mL/min/1.73 m2) were calculated. A similar 
analysis was performed for the models using BSA normal-
ized parameters except log BSA was not used. Cabazitaxel 
unbound fraction was measured longitudinally in each patient. 
To estimate cabazitaxel unbound fraction, a linear mixed 
model was used with log BSA, log CrCL at screening and 
time as fixed effects, and random intercept and time slope as 
random effects.
Results
Patient characteristics
Of 32 patients screened, 25 were enrolled between April 
2012 and November 2013 including eight in Cohort A 
(normal renal function), eight in Cohort B (moderate renal 
impairment) and nine in Cohort C (severe renal impair-
ment; Table 1). No patients failed screening due to renal 
function. All 25 patients were Caucasian and there was 
a balanced male/female distribution across all cohorts 
(Table 1). Baseline liver function appeared consistent 
across the cohorts with similar rates of hypoalbuminemia 
(Cohort A: 0; Cohort B: 1/8; Cohort C: 1/9), increased 
alkaline phosphatase levels (Cohort A: 4/8; Cohort B: 
3/8; Cohort C: 2/9), and increased aspartate aminotrans-
ferase levels (Cohort A: 0; Cohorts B: 1/8; Cohort C: 1/9), 
reported at baseline for the three cohorts. Most patients 
(60%) had received ≥3 prior anticancer therapies, prior 
surgery had been performed in 80%, and prior radiation 
therapy had been administered to 48% of patients. Median 
CrCL at baseline was 96.8 mL/min in patients with nor-
mal renal function (Cohort A), 44.6 mL/min in patients 
with moderate renal impairment (Cohort B) and 25.2 mL/
min in patients with severe renal impairment (Cohort C). 
The CrCL remained stable in all patients during the study 
period (Fig. 1). 
Treatment characteristics
A total of 140 cycles of cabazitaxel were delivered to 
25 patients. The median number of cabazitaxel cycles 
administered was three (range 1–20; Table 1). The 
median number of cabazitaxel cycles was similar for 
patients with varying degrees of renal function, and 
median relative dose intensity was >90% in all cohorts. 
The median duration of study treatment was also simi-
lar between cohorts (Table 1). More than one cycle of 
cabazitaxel 25 mg/m2 was received by all eight patients 
with normal renal function (Cohort A) and seven of eight 
patients with moderate renal impairment (Cohort B). 
The remaining patient in Cohort B received cabazitaxel 
25 mg/m2 in Cycle 1 only and then received 20 mg/m2 in 
Cycle 2, following dose reduction due to febrile neutro-
penia. Of the nine patients with severe renal impairment 
in Cohort C who received a cabazitaxel starting dose of 
20 mg/m2, four patients had a dose escalation to 25 mg/
m2 (three patients at Cycle 2 and one patient at Cycle 3). 
The remaining five patients did not receive dose esca-
lations because of DLTs (n = 3) and investigator deci-
sion (n = 2). In Cohort C, one DLT of grade 3 febrile 
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Table 1  Baseline patient characteristics and treatment characteristics
Cohort A
(normal renal 
function)
25 mg/m2
n = 8
Cohort B
(moderate renal 
impairment)
25 mg/m2
n = 8
Cohort C (severe renal impairment) All patients
N = 25
All patients
(starting dose 
20 mg/m2)
n = 9
Received only
20 mg/m2
n = 5a
Escalated to
25 mg/m2
n = 4
Patient characteristics
Male/female, n 2/6 4/4 5/4 3/2 2/2 11/14
Age, years, median 
(range)
58.5 (38–72) 65.0 (42–77) 66.0 (44–77) 69.0 (61–77) 63.0 (44–75) 62.0 (38–77)
ECOG performance status, n
 0 5 1 2 2 0 8
 1 3 6 7 3 4 16
 2 0 1 0 0 0 1
Months since 
diagnosis, median 
(range)
51.8 (6.6–113.4) 37.2 (8.6–460.7) 44.0 (15.5–154.7) 84.6 (15.5–154.7) 41.0 (25.4–55.6) 44.0 (6.6–460.7)
Primary tumor site, n
 Breast 2 0 0 0 0 2
 Cervix 0 2 1 0 1 3
 Colon/rectum 3 0 2 1 1 5
 Esophagus 0 2 0 0 0 2
 Ovary 1 1 0 0 0 2
 Pancreas 1 1 0 0 0 2
 Prostate 0 0 2 1 1 2
 Otherb 1 2 4 3 1 7
Tumor histology, n
 Adenocarcinoma 6 3 5 2 3 14
 Carcinoma 1 4 1 1 0 6
 Sarcoma 0 1 1 1 0 2
 Other 1 0 2 1 1 3
Extent of disease at study entry, n
 Locally advanced 0 0 1 1 0 1
 Metastatic 8 8 8 4 4 24
Prior anticancer regimens, n
 1 1 1 3 2 1 5
 2 1 3 1 1 0 5
 ≥3 6 4 5 2 3 15
Prior taxane 
therapy, n
4 4 3 0 3 11
Creatinine clear-
ance, mL/min, 
median (range)
96.78 
(93.3−101.1)
44.60  
(38.8−49.9)
25.24  
(8.0−29.0)
15.06  
(8.0−25.2)
27.40  
(26.5−29.0)
44.39  
(8.0−101.1)
Treatment characteristics
Cabazitaxel cycles, n
 Total 45.0 41.0 54.0 39.0 15.0 140.0
 Median per 
patient (range)
5.0 (2–13) 3.0 (1–15) 5.0 (1–20) 6.0 (1–20) 4.0 (2–5) 3.0 (1–20)
Relative dose 
intensity, mg/m2/
week, median 
(range)
91.6 (79.2–99.8) 99.7 (70.2–101.1) 99.0 (88.8–99.9) 99.3 (92.3–99.9) 98.6 (88.8–99.9) 98.3 (70.2–101.1)
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neutropenia led to dose reduction to 15 mg/m2 at Cycle 2. 
No patient received two reductions of cabazitaxel dose, 
and no patient had dose interruptions.
Pharmacokinetics
Cabazitaxel PK data were obtained from 25 treated patients 
and 24 were eligible for PK analysis (eight per cohort). One 
patient (Cohort C) was excluded due to protocol deviation. 
PK parameters obtained using non-compartmental analysis 
and three-compartmental analysis (individual modeling) are 
shown in Table 2. For patients with moderate or severe renal 
impairment (versus patients with normal renal function), 
there appeared to be no associations between CL/BSA or 
AUC normalized to dose (AUC/dose), and degree of renal 
impairment. Mean CL/BSA observed was similar across all 
patients with normal renal function (33.5 L/h/m2; geometric 
mean 32.5 L/h/m2), moderate renal impairment (28.9 L/h/
m2; geometric mean 26.5 L/h/m2) and severe renal impair-
ment (29.6 L/h/m2 for patients receiving 25 and 20 mg/m2 
combined; geometric mean 27.0 L/h/m2). The effect of renal 
impairment on cabazitaxel PK parameters was evaluated 
in patients with moderate and severe renal impairment in 
comparison with patients with normal renal function using 
a regression model of patient PK parameters from the PK 
population using CrCL values obtained at screening. The 
primary linear regression of log-transformed parameters 
(AUC/dose and CL/BSA) versus log-transformed CrCL is 
shown in Fig. 2. Estimated slopes of linear regression for 
log PK parameters versus log CrCL were 0.06 (90% CI 
−0.15, 0.28) for CL/BSA and −0.07 (90% CI −0.30, 0.16) 
a In Cohort C, one patient had a cabazitaxel dose reduction to 15 mg/m2 at Cycle 2; this patient received a 20 mg/m2 dose at Cycle 1 and was 
therefore included in the PK population and assessed at Cycle 1
b One patient each with the following primary tumor sites: skin (Cohort A), adrenal gland (Cohort B), lung (Cohort B), bladder (Cohort C, 
20 mg/m2), muscle/soft tissue (Cohort C, 20 mg/m2), peritoneum (Cohort C, 20 mg/m2) and uterus (Cohort C, 25 mg/m2)
ECOG Eastern Cooperative Oncology Group
Table 1  continued
Cohort A
(normal renal 
function)
25 mg/m2
n = 8
Cohort B
(moderate renal 
impairment)
25 mg/m2
n = 8
Cohort C (severe renal impairment) All patients
N = 25
All patients
(starting dose 
20 mg/m2)
n = 9
Received only
20 mg/m2
n = 5a
Escalated to
25 mg/m2
n = 4
Duration of study 
treatment, weeks, 
median (range)
15.1 (6.0–46.0) 9.0 (3.0–52.1) 15.1 (3.0–65.3) 18.0 (3.0–65.3) 12.1 (6.7–15.3) 11.0 (3.0–65.3)
Discontinued treat-
ment, n (%)
8 (100) 8 (100) 9 (100) 5 (100) 4 (100) 25 (100)
 Adverse event 0 2 (25.0) 1 (11.1) 1 (20.0) 0 3 (12.0)
 Poor compliance 
to protocol
0 0 0 0 0 0
 Disease progres-
sion
7 (87.5) 4 (50.0) 4 (44.4) 0 4 (100) 15 (60.0)
 Lost to follow-up 0 0 0 0 0 0
 Patient request 0 1 (12.5) 1 (11.1) 1 (20.0) 0 2 (8.0)
 Other reason 1 (12.5) 1 (12.5) 3 (33.3) 3 (60.0) 0 5 (20.0)
0
20
40
60
80
100
120
140
-120 -80 -40 0 40 80 120
Time relative to cabazitaxel administration (T = 0)
used for pharmacokinetic assessment, Days
Creatinine clearance (mL/min/1.73 m2)
Normal
Moderate
Severe
Fig. 1  Creatinine clearance levels observed during the study period; 
an example observation window of 120 days before to 120 days after 
cabazitaxel administration and pharmacokinetic assessment is pre-
sented
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for AUC/dose. For primary PK parameters, linear regres-
sion analysis showed no meaningful increase in cabazitaxel 
dose-normalized exposure (AUC/dose: p = 0.5961) and no 
meaningful decrease in cabazitaxel CL/BSA (p = 0.6268) 
associated with the decrease in CrCL (increased renal 
impairment) within the range of 8.03–101 mL/min. 
Table 2  Pharmacokinetic parameters
a n = 4; three patients were not included in the statistical analysis for Cycle 1 (20 mg/m2) because they were analyzed at Cycle 2 (25 mg/m2)
b n = 4; one patient was excluded from statistical analyses because the cabazitaxel dose was decreased to 15 mg/m2
c n = 7; one patient was excluded from the calculation of summary statistics because of a sampling time deviation at the end of infusion
AUC Area under the plasma concentration–time curve, CL clearance, CL/BSA clearance normalized to body surface area, Cmax maximum plasma 
concentration, CV coefficient of variation, SD standard deviation, t1/2γ3 elimination half-life, Vss volume of distribution at steady state, Vss/BSA 
volume of distribution at steady state normalized to body surface area
Parameter, mean ± SD (geometric mean) [CV  %] Cohort A
(normal renal function)
25 mg/m2
n = 8
Cohort B
(moderate renal impairment)
25 mg/m2
n = 8
Cohort C
(severe renal impairment)
20 mg/m2
n = 4a
25 mg/m2
n = 4b
Non-compartmental analysis
 Cmax, ng/mL 161 ± 57.0
(152) [35]
241 ± 207c
(193) [86]
135 ± 45.7
(130) [34]
244 ± 150
(215) [62]
Individual modeling/three-compartmental analysis
 AUC, ng*h/mL 787 ± 177
(766) [23]
1070 ± 733
(938) [68]
928 ± 475
(829) [51]
857 ± 263
(823) [31]
 CL, L/h 58.9 ± 14.7
(57.5) [25]
54.1 ± 21.9
(49.1) [41]
51.8 ± 34.4
(44.8) [66]
63.0 ± 30.5
(58.1) [48]
 Vss, L 7730 ± 3280
(7160) [42]
6730 ± 2970
(6170) [44]
5810 ± 1360
(5690) [23]
6470 ± 3790
(5680) [59]
 CL/BSA, L/h/m2 33.5 ± 9.76
(32.5) [29]
28.9 ± 10.7
(26.5) [37]
27.5 ± 17.1
(24.1) [62]
31.7 ± 11.4
(30.3) [36]
 Vss/BSA, L/m
2 4230 ± 1360
(4040) [32]
3580 ± 1480
(3320) [41]
3130 ± 730
(3060) [23]
3380 ± 1920
(2970) [57]
 t1/2γ3, h 122 ± 43.8
(116) [36]
143 ± 102
(124) [71]
133 ± 84.4
(113) [63]
115 ± 49.8
(103) [43]
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Fig. 2  Estimated slope of linear regression for log pharmacokinetic parameters versus creatinine clearance
1192 Cancer Chemother Pharmacol (2016) 78:1185–1197
1 3
Estimates for the geometric mean ratios of PK parame-
ters for the renal impairment groups (moderate and severe) 
versus an estimated control group were determined from 
the linear regression model (Table 3). Log CrCL val-
ues corresponding to the mean boundaries of the CrCL 
interval covering the patient cohorts with moderate renal 
impairment (40 mL/min/1.73 m2) and severe renal impair-
ment (15 mL/min/1.73 m2) were used, versus a value rep-
resenting the normal population and defined as the control 
group (90 mL/min/1.73 m2). The geometric mean ratio for 
AUC in patients with severe renal impairment versus nor-
mal renal function (1.14; 90% CI 0.76, 1.71) indicated no 
significant impact of renal impairment. For CL/BSA, the 
geometric mean ratio for patients with severe renal impair-
ment versus patients with normal renal function was 0.89 
(90% CI 0.61, 1.32). The predicted CL/BSA for patients 
with severe renal impairment or normal renal function 
was 26.66 and 29.81 L/h/m2, respectively, which accounts 
for a maximal decrease in cabazitaxel clearance of 10.6% 
and indicates no meaningful change in CL/BSA with 
increased renal impairment. Some secondary PK parame-
ters appeared to have trend for association with decreasing 
renal function; in particular, Vss/BSA was approximately 
2700 L/m2 for patients with severe renal impairment ver-
sus approximately 4000 L/m2 for patients with normal 
renal function. The log of the linear regression slope was 
0.22 (90% CI 0.02, 0.41), indicating that this trend was 
marginally statistically significant. Results from a sensitiv-
ity analysis, where CrCL changes during the time course 
of the study were taken into account, showed similar 
findings.
The estimated unbound fraction of cabazitaxel was low 
and consistent across the different renal function cohorts 
(5.36–5.51), indicating that renal impairment had no mean-
ingful effect on the cabazitaxel unbound fraction. This was 
further supported by the primary linear regression analysis 
and subsequent estimated slope of linear regression (0.02; 
90% CI −0.05, 0.08). Unbound drug PK analysis would 
therefore lead to the same conclusions as for total drug.
Safety
All patients experienced at least one treatment-emergent 
AE (TEAE) of any grade. Twenty-three patients (92%) 
experienced a treatment-related TEAE, which was grade 
3–4 in 12 patients (48%). A treatment-related serious TEAE 
occurred in eight patients (32%). There were no specific 
patterns of AEs associated with renal impairment. For the 
most frequently reported TEAEs, incidence rates were not 
notably different between patients with different levels of 
renal function. The most frequent treatment-related grade 
3–4 TEAE was febrile neutropenia in six patients (24%), 
including one patient with normal renal function (Cohort 
A, 12.5%), three patients with moderate renal impair-
ment (Cohort B, 37.5%) and two patients with severe renal 
impairment (Cohort C, 22.2%), followed by diarrhea in 
three patients (12%), comprising two patients with moder-
ate renal impairment (Cohort B, 25%) and one patient with 
Table 3  Estimated pharmacokinetic parameters for specified levels of renal function (CrCL)
a Specified CrCL values correspond to the mean boundaries of the CrCL interval covering the patient cohorts with moderate renal impairment 
(40 mL/min/1.73 m2) and severe renal impairment (15 mL/min/1.73 m2), versus a value representing the normal population and defined as the 
control group (90 mL/min/1.73 m2)
b Model is linear regression: log (CL/BSA) = log (CrCL) + Error
c Model is linear regression: log (AUC/dose) = log (CrCL) + log (BSA) + Error
d Model is linear mixed: log (fraction unbound) = log (CrCL) + log (BSA) + Time + (b0 + b1 × Time) + Error
AUC/dose Area under the plasma concentration–time curve normalized to dose, CI confidence interval, CL/BSA clearance normalized to body 
surface area, CrCL creatinine clearance, FU unbound fraction
Normal renal function
(CrCL 90 mL/min/1.73 m2)a
Moderate renal impairment
(CrCL 40 mL/min/1.73 m2)a
Severe renal impairment
(CrCL 15 mL/min/1.73 m2)a
Geometric mean estimate (90% CI)
 CL/BSAb, L/h/m2 29.81 (24.18–36.75) 28.34 (24.44–32.86) 26.66 (20.15–35.27)
 AUC/dosec, ng*h/mL/mg/m2 33.23 (26.65–41.44) 35.21 (30.24–40.99) 37.75 (28.29–50.39)
 Vss/BSA
b, L/m2 3991.24 (3305.36–4819.44) 3345.54 (2927.74–3822.96) 2702.50 (2100.18–3477.57)
 Cabazitaxel FU
b, % 5.51 (5.08–5.96) 5.44 (5.13–5.76) 5.36 (4.95–5.80)
Geometric mean ratios versus normal renal function (90% CI)
 CL/BSAb, L/h/m2 – 0.95 (0.80–1.13) 0.89 (0.61–1.32)
 AUC/dosec, ng*h/mL/mg/m2 – 1.06 (0.88–1.27) 1.14 (0.76–1.71)
 Vss/BSA
b, L/m2 – 0.84 (0.72–0.98) 0.68 (0.48–0.96)
 CabazitaxelFU
d, % – 0.99 (0.94–1.04) 0.97 (0.87–1.09)
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Table 4  Summary of treatment-emergent adverse events (TEAEs) and laboratory abnormalities
Patients, n (%) Cohort A
(normal renal function)
25 mg/m2
n = 8
Cohort B
(moderate renal 
impairment)
25 mg/m2
n = 8
Cohort C (severe renal impairment) All patients
N = 25
All patients
(starting dose 20 mg/
m2)
n = 9
Received only
20 mg/m2
n = 5a
Escalated to
25 mg/m2
n = 4
Grade 3–4 TEAEs, 
n (%)
6 (75.0) 5 (62.5) 8 (88.9) 5 (100) 3 (75.0) 19 (76.0)
Grade 3–4 treatment-related TEAEs, n (%)
 Any 4 (50.0) 3 (37.5) 5 (55.6) 4 (80.0) 1 (25.0) 12 (48.0)
 Diarrhea 0 2 (25.0) 1 (11.1) 1 (20.0) 0 3 (12.0)
 Asthenia 1 (12.5) 0 0 0 0 1 (4.0)
 Dizziness 0 0 1 (11.1) 0 1 (25.0) 2 (8.0)
 Fatigue 0 1 (12.5) 0 0 0 1 (4.0)
 Abdominal pain 0 1 (12.5) 0 0 0 1 (4.0)
 Febrile neutropenia 1 (12.5) 3 (37.5) 2 (22.2) 1 (20.0) 1 (25.0) 6 (24.0)
 Soft tissue infection 1 (12.5) 0 0 0 0 1 (4.0)
Grade 3–4 hematologic TEAEs of any causalityb, n (%)
 Anemia 1 (12.5) 1 (12.5) 1 (11.1) 1 (20.0) 0 3 (12.0)
 Leukopenia 7 (87.5) 7 (87.5) 6 (66.7) 3 (60.0) 3 (75.0) 20 (80.0)
 Neutropenia 7 (87.5) 7 (87.5) 7 (77.8) 4 (80.0) 3 (75.0) 21 (84.0)
 Lymphopenia 3 (37.5) 4 (50.0) 3 (33.3) 2 (40.0) 1 (25.0) 10 (40.0)
Grade 3–4 laboratory abnormalities of any causality, n (%)
 Alkaline phosphatase 
increased
1 (12.5) 0 0 0 0 1 (4.0)
 Hypercalcemia 2 (25.0) 0 0 0 0 2 (8.0)
 Creatinine increased 0 0 4 (44.4) 4 (80.0) 0 4 (16.0)
 Hyperkalemia 0 0 1 (11.1) 1 (20.0) 0 1 (4.0)
 Hypokalemia 0 0 1 (11.1) 0 1 (25.0) 1 (4.0)
 Hypermagnesmia 0 0 2 (22.2) 1 (20.0) 1 (25.0) 2 (8.0)
 Blood bilirubin 
increased
1 (12.5) 0 0 0 0 1 (4.0)
All  
grades
Grade  
3–4
All  
grades
Grade  
3–4
All 
grades
Grade 
3–4
All 
grades
Grade 
3–4
All 
grades
Grade 
3–4
All 
grades
Grade 
3–4
Renal and urinary TEAEs of any causality, n (%)
 Any renal and 
urinary disorder
3 (37.5) 0 1 (12.5) 0 1 (11.1) 0 1 (20.0) 0 0 0 5 (20.0) 0
 Dysuria 1 (12.5) 0 0 0 0 0 0 0 0 0 1 (4.0) 0
 Renal colic 1 (12.5) 0 0 0 0 0 0 0 0 0 1 (4.0) 0
 Non-infective 
cystitis
1 (12.5) 0 0 0 0 0 0 0 0 0 1 (4.0) 0
 Hematuria 1 (12.5) 0 0 0 0 0 0 0 0 0 1 (4.0) 0
 Acute renal 
failure
0 0 1 (12.5) 0 0 0 0 0 0 0 1 (4.0) 0
 Urinary retention 0 0 0 0 1 (11.1) 0 1 (20.0) 0 0 0 1 (4.0) 0
Discontinuations due to TEAEs, n (%)
Any TEAE lead-
ing to treatment 
discontinuation
0 0 2 (25.0) 2 (25.0) 1 (11.1) 1 (11.1) 1 (20.0) 1 (20.0) 0 0 3 (12.0) 3 (12.0)
 Cholecystitis, 
infective
0 0 1 (12.5) 1 (12.5) 0 0 0 0 0 0 1 (4.0) 1 (4.0)
 Colitis, ischemic 0 0 0 0 1 (11.1) 1 (11.1) 1 (20.0) 1 (20.0) 0 0 1 (4.0) 1 (4.0)
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severe renal impairment (Cohort C, 11.1%; Table 4). The 
most frequent grade 3–4 hematologic TEAE based on labo-
ratory assessments was neutropenia which was reported 
in 21 patients (84%) including seven patients from each 
cohort of patients (Cohort A, 87.5%; Cohort B, 87.5%; 
Cohort C, 77.8%), followed by leukopenia in 20 patients 
(80%), comprising seven patients with normal renal func-
tion (Cohort A, 87.5%), seven patients with moderate renal 
impairment (Cohort B, 87.5%) and six patients with severe 
renal impairment (Cohort C, 66.7%; Table 4). Grade 3–4 
laboratory abnormalities, such as isolated electrolyte imbal-
ances, were reported in a small number of patients and are 
anticipated in this population of advanced cancer patients 
with renal insufficiency and some with possible paraneo-
plastic syndromes (Table 4). There was no specific pattern 
of abnormality detected. Differences among cohorts in the 
number of patients presenting with creatinine increase were 
also anticipated and were directly related to their renal 
function status. No grade 3–4 TEAEs related to renal and 
urinary toxicity were observed in any patient (a detailed 
overview of TEAEs is displayed in Table 4).
Patients with severe renal impairment in Cohort C were 
assessed for DLTs during Cycle 1 as part of the dose esca-
lation determination. Three patients in Cohort C experi-
enced a DLT during Cycle 1, including grade 3 febrile neu-
tropenia, grade 3 diarrhea and grade 3 neutropenia.
Three patients (12%) discontinued treatment because of 
a TEAE (Table 4). Of patients with moderate renal impair-
ment (Cohort B), two patients discontinued cabazitaxel 
because of treatment-related diarrhea (n = 1) and a serious 
AE (cholecystitis; n = 1) considered unrelated to treatment. 
Of patients with severe renal impairment (Cohort C), one 
patient receiving cabazitaxel 20 mg/m2 discontinued treat-
ment because of serious AEs (ischemic colitis and pneumo-
nia) considered unrelated to treatment.
Efficacy
Efficacy assessments were not an objective of this study, 
but tumor response by RECIST criteria was evaluated per 
the investigators usual practice. Partial response was seen 
in two patients (8%) including one patient in Cohort A with 
breast cancer and one patient in Cohort C with bladder 
cancer. Stable disease was reported in 11 patients (44%) 
and progressive disease in nine patients (36%). Three 
patients were not evaluable for tumor response or did not 
have measurable disease at baseline.
Discussion and conclusions
Patients with renal or hepatic impairment are generally 
excluded from phase I clinical trials due to the challenges 
they present [26], therefore most cancer treatments are 
approved with limited information on their PK in these 
patient populations. PK and safety studies in patients with 
renal impairment may be requested by regulatory authori-
ties at the time of treatment approval, although many stud-
ies are conducted post-approval. The primary goal of phase 
I PK studies in patients with impaired renal function is 
to determine whether the PK is altered to such an extent 
that the dosage should be adjusted from the established, 
approved dose. There are many previous and ongoing PK 
studies performed in cancer patients [26–32]. For exam-
ple, oxaliplatin and imatinib PK studies concluded that, 
even though drug clearance may be decreased and expo-
sure increased, treatments were well tolerated and no dose 
reduction was necessary in patients with mild-to-moderate 
renal impairment [27, 28]. For other treatments such as 
vinflunine, pemetrexed and eribulin, PK studies supported 
a dose reduction from the approved dose in patients with 
renal impairment [29, 30, 32].
Since cabazitaxel is only minimally excreted via the 
kidneys (3.7 with 2.3% excreted as unchanged drug) [15], 
it was considered unlikely that renal impairment would 
influence the PK of cabazitaxel. This article details the 
results of the first study conducted to assess the safety 
and PK of cabazitaxel in patients with moderate or severe 
renal impairment, as this population of patients have been 
excluded from prior studies of cabazitaxel or minimally 
represented. In a previous population PK analysis of 
cabazitaxel, patients with moderate or severe renal impair-
ment accounted for less than 10% of the patient popu-
lation (15/170) [16]. The current phase I PK and safety 
study confirms the findings of the previous PK population 
analysis that cabazitaxel dose modification is not required 
a In Cohort C, one patient had a cabazitaxel dose reduction to 15 mg/m2 at Cycle 2; this patient received a 20 mg/m2 dose at Cycle 1 and was 
therefore included in the PK population and assessed at Cycle 1
b Hematoloigc TEAEs based on laboratory abnormalities
Table 4  continued
All  
grades
Grade  
3–4
All  
grades
Grade  
3–4
All 
grades
Grade 
3–4
All 
grades
Grade 
3–4
All 
grades
Grade 
3–4
All 
grades
Grade 
3–4
 Diarrhea 0 0 1 (12.5) 1 (12.5) 0 0 0 0 0 0 1 (4.0) 1 (4.0)
 Pneumonia 0 0 0 0 1 (11.1) 0 1 (20.0) 0 0 0 1 (4.0) 0
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for patients with moderate or severe renal dysfunction as 
renal impairment had no meaningful effect on the PK of 
cabazitaxel. Increasing renal impairment did not result in 
any meaningful increase in cabazitaxel dose-normalized 
exposure or decrease in cabazitaxel CL/BSA. Cabazitaxel 
clearance was similar regardless of renal impairment and 
was within the range of values observed in previous stud-
ies in patients with advanced solid tumors [16, 24, 25]. In 
two phase I studies, the mean cabazitaxel clearance rates 
were high (27.3–44.7 L/h/m2) [24, 25]. In the population 
PK assessment of cabazitaxel in patients with advanced 
solid tumors from five different studies, including the two 
phase I studies (total: n = 170; ranging between n = 13 and 
n = 67), the mean clearance of cabazitaxel ranged from 
12.1 to 34.5 L/h/m2 [16], which was lower than those val-
ues obtained from the individual modeling [24, 25]. The 
population PK analysis allowed for a better estimation of 
the PK parameters from the phase I studies as the impact of 
sample times was reduced. Renal impairment also had no 
meaningful effect on the unbound fraction of cabazitaxel, 
which is consistent with the high binding of cabazitaxel to 
total plasma proteins observed ex vivo and in vitro (89–
92%) [16, 25, 33].
The trends in PK parameters associated with renal func-
tion were not considered clearly established for any param-
eter because of the large variability in parameters that was 
not well accounted for by the linear regression models, 
indicating a limitation of the methodology. This was dem-
onstrated by the lack of precision (large confidence inter-
vals) in the estimates of both geometric mean ratios and 
point parameters in patients with severe renal impairment. 
In addition, outlier values in different parameters were seen 
in different patients. Including a cohort of patients with 
mild renal impairment in this study would have allowed for 
assessments over a wider range of renal function and pro-
vided information for patients with CrCL levels falling into 
the ≥50 to ≤80 mL/min/1.73 m2 interval, which may have 
refined the linear regression models. Patients with mild 
renal impairment were not included because cabazitaxel 
is minimally excreted by the kidneys, meaning that assess-
ment of cabazitaxel in patients with moderate or severe 
renal impairment would provide the most clinically rel-
evant information. In our opinion, the findings in patients 
with moderate or severe renal impairment suggest that fur-
ther studies in patients with mild renal impairment are not 
required. However, for studies of new agents where the PK 
of certain treatments may be affected by renal impairment, 
obtaining data from a patient population spanning a con-
tinuous range of CrCL levels and including patients with a 
complete series of renal function and impairment, may be 
an ideal approach.
The overall safety and AE profile of cabazitaxel 
observed in patients with normal or moderate renal 
impairment in this study was consistent with the known 
safety profile of cabazitaxel, and no new safety issues were 
identified. For the most frequently reported TEAEs, inci-
dence rates were similar for patients with different levels of 
renal function. The low rate of AEs related to renal toxicity 
in patients with renal impairment suggests that renal func-
tion does not decrease during cabazitaxel treatment. The 
overall rate of grade 3–4 neutropenia in this study, based 
on laboratory assessments, was 84%. This is similar to the 
rate of neutropenia reported in the phase III TROPIC trial 
(94% all grades, 82% grade 3–4) [14]. The overall rate of 
grade 3–4 febrile neutropenia in this study was 24%, com-
pared with 8% in TROPIC. This apparent difference could 
be due to the smaller number of patients, the heterogeneous 
patient population, or the more heavily pretreated patient 
population, in this phase I study compared with TROPIC.
Patients with mild-to-moderate renal impairment pose 
an increasingly frequent challenge for clinicians. Taking 
into consideration the results of this study and other studies 
assessing the PK and safety of treatments in patients with 
renal dysfunction, patients with renal impairment could be 
considered for entry into selected phase I studies of treat-
ments with low renal clearance, where it is deemed unlikely 
that renal impairment would affect drug PK [26]. This will 
provide data for new agents in this patient population ear-
lier and increase patient access to clinical trials and experi-
mental treatments. Furthermore, results from such PK stud-
ies would inform regulatory authorities as to whether dose 
modifications should be recommended for certain patient 
subpopulations.
In summary, the data support the clinical recommenda-
tion that full doses of cabazitaxel (25 mg/m2) can be safely 
administered every 3 weeks to patients with mild-to-severe 
renal dysfunction.
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